StockData
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$0.83−0.01 (-0.93%)

Close on Nov 11, 2026Market cap $149.51MP/E –Yield –

Earnings

Compass Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.15
-$0.08 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Compass Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open––-$0.15Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open––-$0.13Release
Q1 FY2026ended Mar 31, 2026May 5, 2026before the open––-$0.10Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026before the open––-$0.09Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open––-$0.08Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025before the open––-$0.14Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open––-$0.12Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open––-$0.11Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open––-$0.08Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024before the open$850.00K–-$0.10Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open––-$0.08Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Compass Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Compass Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Compass Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
    Results
  2. Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
    Update
  3. Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
    Results
  4. 8-K exhibit EX-99.1
    Update
  5. Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
    Results
  6. Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
    Update
  7. Corporate Presentation Nasdaq: CMPX April 27, 2026
    Update
  8. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
    Results
  9. Compass Therapeutics Provides Corporate Update
    Results
  10. Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Results
  11. Compass Therapeutics Announces Proposed Public Offering
    News
  12. Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
    News
  13. Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
    Results
  14. Thomas Schuetz, MD, PhD CEO and Co - founder
    Results
  15. Corporate Presentation Nasdaq: CMPX August 2025
    Results

See a number that looks wrong?